What Cisaprida treats: main uses and benefits

The therapeutic domain for cisaprida involves addressing conditions associated with impaired movement within the digestive tract, which presents with symptoms that interfere with daily functioning, such as physical discomfort and delayed gastric emptying. It is commonly used to help with conditions where symptoms may intensify temporarily, such as severe reflux oesophagitis and gastroparesis. These are conditions involving episodic or fluctuating manifestations and symptoms linked to organ-specific functional stress.

Cisaprida's use is part of symptomatic management for certain motility-related gastrointestinal disorders. The medication may assist with maintaining functional stability of the digestive system in clinical scenarios involving chronic idiopathic constipation, severe reflux oesophagitis, and gastroparesis.

The medication contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations. It is relevant for easing symptoms that create noticeable physiological strain and supports patients during episodes of heightened discomfort.

Quick Fact: Supports management of symptoms related to physical discomfort.

Regulatory References

1. European Medicines Agency (EMA) opinion on use

Cisaprida's eligibility profile is primarily defined by absolute contraindications and severe restrictions imposed by regulatory authorities due to the risk of serious cardiac arrhythmias. Its use in humans is highly restricted in many major markets.

Contraindicated Populations (Must Not Use)

Cisaprida is contraindicated in patients with a history of ventricular arrhythmias, ischemic heart disease, congestive heart failure, or clinically significant bradycardia. It must not be used by individuals with a prolonged QT interval or a family history of congenital long QT syndrome.

Use is prohibited in the presence of uncorrected electrolyte disturbances (such as hypokalemia) or conditions where increased gastrointestinal motility is dangerous, including gastrointestinal hemorrhage, mechanical obstruction, or perforation.

Age- and Condition-Based Restrictions

Use is not recommended during pregnancy or lactation unless the benefit outweighs the risk, as the substance is excreted in breast milk. Eligible patients in restricted-access programs must undergo mandatory cardiac monitoring.

The official interaction profile for Cisaprida is structured by two primary regulatory concerns: metabolic inhibition and pharmacodynamic effects on cardiac rhythm.

Contraindicated Combinations and Restrictions

Co-administration is formally contraindicated with numerous medicinal products. This restriction applies to all strong inhibitors of the Cytochrome P450 3A4 (CYP3A4) enzyme, which is the major pathway for Cisaprida clearance. Combining with CYP3A4 inhibitors (including Macrolide Antibiotics, Azole Antifungals, and HIV Protease Inhibitors) drastically increases Cisaprida's systemic plasma exposure.

The drug is also contraindicated with any medicine known to prolong the QTc interval. This restriction covers Class IA and Class III antiarrhythmics and specific antipsychotic agents, due to a highly significant risk of additive pharmacodynamic effects that can lead to life-threatening ventricular arrhythmias. Furthermore, the substance grapefruit juice is strictly forbidden for co-ingestion as it inhibits intestinal CYP3A4.

Other Documented Interaction Patterns

Cisaprida's prokinetic action can accelerate the rate of absorption of co-administered oral medicines, necessitating careful monitoring for drugs with a narrow therapeutic index, such as oral anticoagulants. Pharmacodynamic interactions are documented with CNS depressants (including alcohol and benzodiazepines), which may experience enhanced sedative effects. Interaction risk is also heightened in populations with hepatic impairment (due to reduced clearance) and in the presence of uncorrected electrolyte disturbances.

Cisapride’s principal action involves the selective agonism of the serotonin 5- HT4 receptor, located on cholinergic efferent neurons within the Enteric Nervous System (ENS). This receptor activation initiates a signal cascade resulting in the augmented release of acetylcholine (ACh) from nerve endings in the myenteric plexus. The resulting physiological effect is the enhancement of nerve-driven smooth muscle excitation throughout the entire digestive tract. The released ACh acts on muscarinic receptors on the smooth muscle, modulating muscle function, leading to coordinated, wave-like peristaltic movements and the accelerated forward transit of contents across the esophagus, stomach, and intestines. Mechanistically distinct from this action, cisapride also acts as an off-target inhibitor of the cardiac hERG potassium ion channel (the IKr current). This ion channel blockade modifies a phase of cardiac electrophysiology, causing a prolonged repolarization period in ventricular cells.

How to use Cisaprida

The administration of cisapride is governed by specific dosing and scheduling requirements with the objective of standardizing its use. The authorized route for cisapride is oral, typically administered as tablets (10 mg or 20 mg) or a 1 mg/mL oral suspension.

The standard adult dosing regimen involves taking 10 mg per dose, four times daily, with the maximum per administration not exceeding 20 mg. A critical instruction is the timing of administration: each dose must be taken at least 15 minutes before meals and a final dose at bedtime. For specific patient populations, the dosage requires modification; for instance, the total daily dose must be reduced by 50% for individuals with hepatic (liver) impairment. Pediatric dosing, for patients over one year, is based on weight at 0.2 to 0.3 mg/kg per dose, given 3 to 4 times a day, not to exceed 10 mg per single dose.

Administration Protocols

Research evidence / Overview of studies for Cisaprida

Evidence for use in Gastroesophageal Reflux (GERD)

Research has examined Cisaprida in individuals with GERD, a condition characterized by fluctuating or episodic manifestations of reflux symptoms. Studies focusing on adults have evaluated the drug while research has explored the drug's role in the movement of food through the upper digestive system. Findings from these trials describe patterns observed in the studies regarding outcomes related to physical discomfort and outcomes describing episodic or acute changes in symptoms. However, the evidence quality varies across studies, and comparative evidence is lacking.

Evidence for use in Gastroparesis (Delayed Stomach Emptying)

Cisaprida was studied for gastroparesis, a condition marked by functional limitations, with research exploring how it may affect the slow movement of the stomach muscles. Research examined the drug’s effect on measurable physiological markers, which are relevant in trials assessing short-term or episodic symptom patterns. In specific populations, such as those with gastroparesis related to diabetes, Cisaprida was evaluated in studies looking at outcomes reflecting daily functioning or activity level. Findings were mixed regarding how effectively these observed changes translated into consistent symptom relief.

Long-term studies and follow-up

Follow-up durations were limited in the majority of studies, which were designed to observe responses over defined time intervals that were relatively short. Consequently, long-term effects are not fully established, and there is limited information for long-term outcomes regarding the use of Cisaprida. Understanding the longer-term outcomes related to systemic or functional imbalance requires more extensive research than is currently available.

What is still uncertain about Cisaprida

A primary area of uncertainty is the varying quality and scope of the research; evidence quality varies across studies, leading to mixed findings in some areas. Specifically, the relationship between measured physiological outcomes and actual patient-reported outcomes describing perceived discomfort is not always clear or consistent across all research. Comparative evidence is lacking to definitively understand how Cisaprida’s effects may compare to other available interventions. The evidence highlights what is known — and what is still uncertain.

Common questions about Cisaprida (FAQ)

Q: Does Cisaprida act differently than antacids or proton pump inhibitors (PPIs)?

Yes, Cisaprida is a prokinetic agent that works by enhancing the natural muscle movement of the digestive tract. This mechanism is distinct from antacids, which neutralize stomach acid, and from Proton Pump Inhibitors (PPIs), which reduce the amount of acid the stomach produces.

Q: Is Cisaprida still available in all countries, or has its status changed?

The drug's status changed globally due to the potential for serious cardiac side effects. Official regulatory actions led to its withdrawal or severe restriction in many major markets, including the United States. Where legally available, it is often confined to specific restricted-access or compassionate-use programs.

Q: Can Cisaprida cause long-term side effects that people should know about?

Long-term effects are not fully established because most studies were conducted over relatively short periods of observation. Regulatory documents state that the severe cardiac risk is the primary reason for the drug's restricted status.

Q: How quickly do people typically start to feel an improvement in symptoms after starting Cisaprida?

Official pharmacodynamic data, which describes the drug's action, indicates the onset of effect on gastric motility (stomach movement) occurs approximately 30 to 60 minutes after taking an oral dose.

Q: Is Cisaprida a medicine intended for short-term use, or can it be used long-term?

Regulatory documents indicate that the medication should be discontinued if a person does not achieve adequate symptomatic relief within the designated therapeutic assessment period.

Q: Can Cisaprida be used by women who are pregnant or breastfeeding, based on official information?

Cisaprida has a pregnancy classification that indicates its use during pregnancy is considered only when the potential benefit is believed to outweigh the potential risk, as described in official labeling. Furthermore, the substance is known to be excreted into human milk, and cautious use during the breastfeeding period is noted in regulatory documents.

Q: Are there any known issues with Cisaprida and kidney or liver function?

Yes, the drug is primarily processed by the liver. Official regulatory documents require that the total daily dose be reduced by 50% for individuals who have hepatic (liver) impairment and recommend dose reduction for patients with kidney insufficiency.

Q: Why is Cisaprida sometimes prescribed even though it has specific safety warnings?

Cisaprida is considered a potent motility stimulant and, where legally available, it is confined to specific compassionate-use programs. This allows use for select patients with severe gastrointestinal motility disorders who have not responded to other treatments.

Q: Is it necessary to take Cisaprida at a specific time relative to meals?

Yes, official instructions emphasize specific timing for administration. Regulatory documents specify that each dose should be taken at least 15 minutes before meals, with a final dose of the day taken at bedtime.

Q: How are Cisaprida's potential risks mitigated in clinical use?

Risk mitigation involves requirements for patient monitoring, which often includes obtaining a baseline heart tracing (ECG) and checking serum electrolytes during treatment. These measures are paired with formal contraindications that restrict its use in patients with existing heart conditions or those taking certain interacting medicines.

Q: Is Cisaprida safe to use for infants and children with gastroesophageal reflux?

Pediatric dosing guidelines for patients over one year are defined in official regulatory documents. However, official safety statements note that use is generally restricted or contraindicated in children under 16. Furthermore, research has not established that it is effective for gastroesophageal reflux disease (GERD) in children.

Q: Does Cisaprida interact with herbal supplements or vitamins?

Regulatory warnings mention the concern for interactions with substances that strongly inhibit the CYP3A4 enzyme, which processes Cisaprida in the body. The official advice is to review all non-prescription medicines, supplements, or herbal therapies with a healthcare provider, due to the potential for serious interactions.

Q: Can Cisaprida cause a dry mouth or increased urination?

Adverse events reported in connection with Cisaprida include dry mouth, which was seen in clinical trials. In postmarketing surveillance, reports of urinary frequency or incontinence have also been documented.

Q: Does Cisaprida have any known effects on mental state or nervous system function?

The regulatory side effect profile lists certain nervous system effects such as drowsiness, headache, and tremor as possible reactions. However, the drug is generally described in clinical literature as being without the central sedative effects of some related medicines.

Q: What are the potential signs of Cisaprida affecting the liver?

Regulatory documents list 'signs of liver problems' as a possible serious reaction. These signs include dark urine, tiredness, decreased appetite, upset stomach or stomach pain, light-colored stools, or yellowing of the skin or eyes.

Q: Can using Cisaprida cause changes in weight or appetite?

Regulatory documents indicate that potential adverse effects associated with Cisaprida may include decreased appetite and unusual weight gain.

Q: Does Cisaprida interact with commonly used pain relievers or anti-inflammatory drugs?

Official regulatory interaction information does not generally list common pain relievers or anti-inflammatory drugs (NSAIDs) as contraindicated. However, the prokinetic action of Cisaprida can speed up the rate at which any co-administered oral medicine is absorbed into the body.

Q: Can Cisaprida be taken by individuals who also have diabetes?

Cisaprida was studied for use in gastroparesis, a condition frequently associated with diabetes. Regulatory summaries do not contain a specific contraindication solely for individuals with diabetes, but they do require general monitoring for any condition that affects electrolyte balance.

Q: What are the official recommendations regarding alcohol consumption while using Cisaprida?

Regulatory warnings state that alcohol is classified as a central nervous system (CNS) depressant. Combining Cisaprida with CNS depressants is documented to potentially enhance their sedative effects.

Q: Does Cisaprida cause an increase in gastric acid production?

Official pharmacodynamic data, which describes the drug's actions in the body, specifies that Cisaprida does not cause an increase or a decrease in the production of gastric acid.

How to Store and Dispose of Cisaprida

The proper storage and disposal of cisapride are strictly governed by regulatory guidelines to ensure stability and safety.

Official Storage Requirements

Regulated Disposal Protocol

The unused or expired product should not be flushed down the toilet or poured into a drain. Disposal should follow official guidance, prioritizing the return of the medication through an authorized drug take-back program. If a take-back option is unavailable, the product must be mixed with an unappealing substance, sealed in a bag or container, and discarded in the household trash.